Fluorescent dextrans as sensitive anterograde neuroanatomical tracers: applications and pitfalls.

We have examined five conjugated 10,000 mol. wt. dextrans as potential anterograde tract tracers: Lucifer Yellow, Texas Red, fluorescein, Cascade Blue and tetramethylrhodamine. Pressure injections were made into the brain, dorsal root ganglia or footpads of adult rats. The retrograde tracer Fluoro-Gold was injected alone or mixed with the dextrans before injection. Three-14 days after injection, animals were perfused and sections cut with a freezing microtome. Texas Red-, fluorescein- and tetramethylrhodamine-conjugated dextrans produced intense labeling of neuronal cell bodies, axons and dendritic processes at the injection site and were transported by neurons predominantly in an anterograde direction to yield terminal and preterminal labeling. Relative to the fluorescein and tetramethylrhodamine conjugates, the quality and intensity of the anterograde labeling produced by Texas Red was variable. Results with Lucifer Yellow and Cascade Blue conjugates were negative. Optimal results were produced by slow-pressure injections via glass micropipettes. In comparison with Fluoro-Gold, retrograde transport by the dextran conjugates was present, but limited in its extent. Injections of the tetramethylrhodamine conjugate into dorsal root ganglia produced anterograde labeling of afferent fibers in visceral organs and injections into the nucleus ambiguous labeled motor fibers in the esophagus. Double/triple labeling was observed in the brain and spinal cord following multiple injections of fluorescein, tetramethylrhodamine and Fluoro-Gold. Also, Fluoro-Gold could be mixed with one of the dextrans in order to produce specific retrograde and anterograde labeling from the same injection site. The conjugates were compatible with fluorescent immunocytochemical procedures, but proved unsuitable for peripheral injections.(ABSTRACT TRUNCATED AT 250 WORDS)     

The effect of perinatal screening in Norway on the magnitude of noninherited risk factors for congenital dislocation of the hip

Several investigators have noted an increase in the rate of congenital dislocation of the hip shortly after the initiation of neonatal screening procedures. This increase has been attributed to the detection of temporarily unstable hips which require no corrective treatment. To test whether neonatal screening had low specificity, the authors obtained data on 17,145 offspring of 7,896 twins from the Norwegian Twin Panel. Information from maternal reproduction history questionnaires was available on the presence or absence of congenital dislocation of the hip, type of obstetric delivery, and parity. The reported prevalence of the disorder did indeed begin to rise sharply during the late 1950s, at which time neonatal screening started in Norway. Infants were then grouped by year of birth (born before or after 1960), and odds ratios were calculated for breech delivery and early (first or second) parity. For the pre-screening group, the odds ratio of congenital dislocation of the hip was 7.7 among children delivered by breech presentation and 2.6 among those of early parity. These values are similar to those found in other studies. In the post-screening group, the odds ratios for breech delivery and early parity were 1.5 and 1.2, respectively. Breech delivery and early parity have been consistent risk factors for congenital dislocation of the hip. Their diminished influence in the post-screening group, as well as sharply increased rates of the disorder, suggests that in Norway neonatal screening programs may have had low specificity in detecting cases that required treatment.     

Neuroblastoma in a patient with Sotos'' syndrome.

Sotos' syndrome, or cerebral gigantism, is a disorder of growth regulation. Tumours have occasionally been reported in children with Sotos' syndrome, but it is uncertain whether this is a coincidence, or whether it is aetiologically related to the underlying disorder of growth. We report a 15 month old child with a paraspinal neuroblastoma and Sotos' syndrome and suggest that children with this condition may be at higher risk for developing tumours than the general population.     

Clinical significance of anti-Yt(b). Report of a case using a 51chromium red cell survival study

Several published reports have documented the variable survival of Yt(a+) red cells (RBC) in patients with anti-Yt(a) as measured by 51Chromium (Cr)-labeled RBC survival studies. Similar studies with anti-Yt(b) have not been reported. A 51Cr-labeled RBC survival study was performed using Yt(b+) RBCs and a monocyte monolayer assay in a young hemodialysis patient who required chronic transfusion therapy and who had developed anti-Yt(b). The survival of the transfused RBCs was 100 and 93 percent at 1 and 24 hours, respectively, with a half life of 21 days at termination of the study (normal, 28 to 32 days). These results showed no evidence of rapid destruction of the Yt(b+) RBCs, indicating that this patient could be transfused safely with blood from Yt(b+) donors. Long-term survival of the 51Cr-labeled Yt(b+) RBCs was shortened moderately, however, a finding that correlated with a slightly abnormal monocyte monolayer assay test.     

骨形态发生蛋白2表达异常与脊柱的融合

目的:综述近几年来国内外对骨形态发生蛋白2表达异常及其基因突变的研究,重点分析突变对脊柱融合的影响,为基因重组骨移植提供理论依据。资料来源:应用计算机检索Medline和Science Direct Online数据库1989-01/2007-01期间与骨形态发生蛋白2表达异常及脊柱融合相关的文章,检索词为"BMP2,BMP,gene mutation,mutation,gene expression,abnormal expression,spinal fusion,bony fusion,bone transplantation",限定文章语言种类为English。同时计算机检索中国期刊全文数据库2000-01/2007-01期间与骨形态发生蛋白2表达异常及脊柱融合相关的文章,检索词为"骨形态发生蛋白2,脊柱融合,骨移植,基因突变,表达异常",限定文章语言种类为中文。资料选择:对资料进行初审,选择有关骨形态发生蛋白2生物学活性、信号转导机制、基因突变、与骨诱导的关系、在脊柱融合中的研究进展的文献,共收集到121篇,排除综述类及重复研究。资料提炼:选择其中有代表性的30篇进行综述,涉及到骨形态发生蛋白2的生物学活性、诱导成骨机制、突变的分子学基础、基因突变及影响蛋白表达异常的其他因素。资料综合:骨移植植骨融合的形成是一个多因子、多基因的过程,涉及到骨生成、骨诱导和骨传导3个环节。骨形态发生蛋白2是骨发育和修复的关键调节剂,骨折愈合时尤其需要。国内外学者对于骨形态发生蛋白2基因的自身突变研究取得了很大进展,已检测出不同部位多个位点的突变。基因变异导致所编码氨基酸发生改变,从而引起相应多肽结构发生变异,影响蛋白质的理化性质。无论是体内的骨形态发生蛋白2抑制因子,突变导致的生物活性改变,还是其增龄性效应,最终都将引起局部骨形态发生蛋白2含量下降及生物学活性减退,可能直接导致脊柱融合术后植骨愈合不良或植骨不愈合的发生。结论:对骨形态发生蛋白2表达异常尤其对其基因进行突变分析,寻找影响植骨融合的遗传学因素,具有非常重要的临床意义。     

Sensitivity and specificity of four assays to detect human T− lymphotropic virus type I or type I/II antibodies

BACKGROUND: Assays that detect human T-lymphotropic virus type I and type II antibody (HTLV-I/II) are widely used in the routine screening of blood donors. STUDY DESIGN AND METHODS: Four commercially available anti-HTLV-I (Fujirebio and Organon Teknika) or -HTLV-I/II assays (Murex and Ortho) were evaluated in various serum panels: A) HTLV-I-positive specimens (n = 41), confirmed by Western blot and polymerase chain reaction; B) a commercially available anti-HTLV-I/II panel; C) serial dilutions of sera from HTLV-I-positive individuals (n = 30), confirmed by immunofluorescence assay and Western blot: D) serial dilutions of HTLV-II-positive blood donors (n = 20), confirmed by Western blot and polymerase chain reaction, and E) sera from first-time blood donors (n = 1055). RESULTS: All four assays elicited reactions in all 82 HTLV-I- positive samples in Panels A, B, and C. Of 32 HTLV-II-positive specimens in Panels B and D, 31 (96.9%) reacted in the Organon Teknika assay and all 32 reacted in the remaining tests. Probit analysis of test results in Panels C and D indicated that the Fujirebio test was the most sensitive assay, followed by Organon Teknika, Ortho, and Murex. The specificities of Fujirebio, Murex, Organon Teknika, and Ortho tests in 1055 first-time blood donors were 99.9, 100, 99.6, and 99.9 percent, respectively. CONCLUSION: All four studied assays for detecting HTLV-I or HTLV-I/II antibodies are appropriate as screening tests.     

紫杉醇药物涂层支架植入术后患者外周血单核细胞中热休克蛋白70的变化：生物材料临床应用近期效果随访

目的:植入材料、靶血管病变特征、术前状态、炎症因子及急性期蛋白均对急性冠状动脉综合征接受支架材料介入治疗后的效果有影响,为验证紫杉醇涂层支架临床应用后材料及宿主的相关反应,实验观察了接受紫杉醇涂层支架介入治疗的急性冠状动脉综合征患者的外周血热休克蛋白70水平变化,并分析其临床意义。方法:①连续性入选2004-12/2006-03在江苏大学附属人民医院行经皮冠状动脉介入治疗的78例急性冠状动脉综合征患者,全部病例均置入紫杉醇药物涂层支架。采用流式细胞仪测定症状发作平均(34.1±16.2)h的外周血单核细胞热休克蛋白70阳性表达水平。②所有患者随访至术后6个月,出现心源性死亡、再次心肌梗死、再发心绞痛、再次血运重建术和继发心衰等主要心脏不良事件者为近期预后不良组,无上述情况者判定为近期预后良好组,用logistic多元回归法分析术前状态、靶血管病变特征、植入支架的各项参数及外周血热休克蛋白70水平与主要心脏不良事件发生率的关系,并以同期健康体检者20例为正常对照组。结果:68例患者完成随访进入结果分析。①外周血热休克蛋白70水平:急性心肌梗死患者和不稳定型心绞痛患者比较差异无统计学意义(P>0.05),但均显著高于正常对照组(P<0.05)。②在多变量的logistic回归分析中,外周血热休克蛋白70独立于其危险因素,能预测急性冠状动脉综合征患者经皮冠状动脉介入治疗后近期主要心脏不良事件发生率(OR值为0.904,P<0.05)。结论:回归分析结果提示,应用紫杉醇涂层支架临床治疗近期效果评估中,外周血热休克蛋白70水平高的急性冠状动脉综合征患者近期心脏事件发生率较高,说明外周血热休克蛋白70可能成为判断紫杉醇涂层支架介入治疗后不良事件发生率的独立因素之一。     

骨唾液酸蛋白在体外培养人骨髓间充质干细胞向成骨细胞分化中的角色

目的：骨唾液酸蛋白在骨矿化形成方面扮演重要角色，实验观察其是否能诱导体外培养的人骨髓间充质干细胞向成骨细胞分化。方法：实验于2005—10／2006—12在解放军广州军区广州总医院医学实验科完成。①材料来源：选取在本院体检的健康志愿者2人，对本实验均知情同意。采用Ni-NTA亲和纯化技术，从本室构建的毕赤酵母GS115／pPICZaA-hbsp发酵上清中纯化重组人骨唾液酸蛋白。②实验方法：对健康志愿者进行髂骨穿刺抽取骨髓液，采用贴壁法培养得到骨髓间充质干细胞。设立4组：骨唾液酸蛋白组添加0．1nmol／L骨唾液酸蛋白；成骨诱导液组添加10nmol／L地塞米松、10mmol／L磷酸甘油、50mg／L抗坏血酸；联合组添加上述两组的所有试剂；空白对照组不添加任何处理因素；各组均处理细胞12d。⑧实验评估：光镜及电镜观察培养的细胞形态；以细胞计数法测定生长曲线，应用流式细胞仪分析细胞周期，采用免疫荧光细胞化学法和流式细胞分析检测干细胞标志物STRO-1的表达；生化试剂盒测定碱性磷酸酶活性；von Kossa染色法检测钙沉积。结果：①单个骨髓间充质干细胞为长梭形，经骨唾液酸蛋白处理后细胞大而扁平，原来密集的克隆分散开。②与空白对照组比较，骨唾液酸蛋白组引起细胞生长曲线右移，细胞Go／G，期比例平均增加12．09％（P〈0．01），S期比例减少65．92％（P〈0．01），STRO-1阳性细胞百分率下降26．54％（P〈0．01）。⑧与空白对照组比较，骨唾液酸蛋白组细胞碱性磷酸酶活性增加50．0％，成骨诱导液组增加59．5％，联合组增加71．43％，并且随着处理时间的延长，活性增加越显著。④空白对照组细胞vonKossa染色呈阴性，其余各组均呈阳性。其中联合组的黑色矿化结节体积最大、数目最多；骨唾液酸蛋白组的结节体积较小、数目较少；成骨诱导液组居中。结论：骨唾液酸蛋白对人骨髓间充质干细胞有促进成骨分化和矿化作用，且与成骨诱导液联用效果更佳。     

骨形态发生蛋白4转基因治疗大鼠的胫骨缺损

目的:观察基因工程技术构建人骨形态发生蛋白4复制缺陷腺病毒的成骨效果。方法:实验于2006-03/08在安徽医科大学第一附属医院实验动物中心完成。实验分组:选取普通级雄性SD大鼠30只,体质量(200±10)g,全部动物胫骨上端部分分别造成8mm×5mm长方形缺损。采用自身对照法,右侧骨缺损为实验组,左侧骨缺损为对照组。实验组植入人骨形态发生蛋白4复制缺陷腺病毒复合明胶海绵,对照组植入单纯明胶海绵。实验评估:术后分别于4,6,8周麻醉后处死10只动物,取材行X线、组织病理、免疫组织化学、透视电镜检查,观察成骨情况。结果:纳入30只大鼠,全部进入结果分析。①大鼠胫骨缺损X线、组织病理学检查结果:术后8周实验组和对照组骨缺损均得到修复,但实验组无论从成骨时间、成骨效果、新生骨量等方面都要优于对照组。其中各时间点实验组骨密度明显高于对照组,差异有显著性意义[4周:(95.91±16.33),(87.93±11.52);6周:(128.34±10.64),(102.41±9.81);8周:(138.36±10.49),(121.56±9.63);P<0.01]。各时间点实验组新生骨占骨缺损面积比明显高于对照组,差异有显著性意义[4周:(41.39±5.65)%,(26.58±5.62)%;6周:(80.35±7.25)%,(65.41±6.52)%;8周:(96.45±2.76)%,(82.22±7.30)%;P<0.01]②术后4周免疫组织化学染色结果:实验组软骨及骨痂内呈强阳性反应,而对照组骨痂内骨形态发生蛋白4表达微弱。结论:人骨形态发生蛋白4重组腺病毒具有良好的成骨活性,骨形态发生蛋白4直接转基因治疗能够加快骨缺损的修复。